Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3
Date:7/6/2009

ng dynamics between ErbB2 and ErbB3 and to exquisitely target cancer cells."

MM-111 has two antibody arms; a targeting arm that binds to ErbB2 with high affinity and a therapeutic arm that binds to ErbB3 (also known as HER3). Both ErbB2 and ErbB3 are members of the ErbB family of receptors, a complex molecular network whose activation is commonly linked with cancer. In 2003, Merrimack researchers identified ErbB3 as a highly sensitive node in the ErbB signaling network and also found it played a dominant role in activation of the PI3 kinase pathway - a pathway believed to be used by cancer cells to sustain survival. The importance of ErbB3 in cancer progression is now widely appreciated. Preclinical data demonstrating the impact of MM-111 in multiple cancer models were presented at the annual meeting of the American Association for Cancer Research in April.

The current Phase 1/2 study will evaluate the human safety and pharmacokinetics (PK) of MM-111. The Phase 1 portion of the study is enrolling patients with tumors that overexpress ErbB2 while the Phase 2 portion of the study will be restricted to ErbB2 overexpressing (HER2+) breast cancer patients. The first dose was administered at South Texas Accelerated Research Therapeutics (START) where enrollment is currently underway. Fox Chase Cancer Center is expected to participate in the trial this July.

"MM-111 has the potential to help patients who are resistant to currently approved ErbB2 therapies," said William J. Slichenmyer, MD, Senior Vice President and Chief Medical Officer at Merrimack. "Preclinical studies of MM-111 have demonstrated that the bispecific approach shows antitumor activity in a wid
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
2. Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
3. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
4. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
5. Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
6. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm
7. Biostar Pharmaceuticals, Inc. Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base
8. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
9. The Crohns & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners
10. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
11. DiaGenic to Provide MCI Biomarkers for Merz Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, iFitDress.com,a ... occasion outfits, has unveiled its new collection of ... made to expand the company’s global market. Each item ... to the company’s senior spokesman, customers that have specific ... at iFitDress.com. Now, all the brand new items are ...
(Date:8/19/2014)... Aug. 19, 2014 (HealthDay News) -- Lupus and ... as headaches and seizures, which can delay a ... Treatments for rheumatic diseases can also cause ... Loyola University Medical Center in Maywood, Ill. ... the joints and soft tissues, such as lupus, ...
(Date:8/19/2014)... Just back from Glasgow where he helped distribute thousands ... Commonwealth Games (July 23 – August 6), Pete Dwan is ... And the need for his work cannot be overstated. , ... 59 consumed Class A drugs within the last year. And ... (NPS) drugs considered to be “legal highs” until June 2014, ...
(Date:8/19/2014)... Warfarin, the longtime standard treatment for atrial fibrillation, ... anticoagulant drug marketplace including dabigatran, rivaroxaban, and apixaban. ... these novel oral anticoagulants (NOACs) into clinical practice. ... new anticoagulant prescriptions yet this represents 98% of ... The American Journal of Medicine . , ...
(Date:8/19/2014)... City, Utah (PRWEB) August 19, 2014 ... Benefits Solution, published a new guide on compliance ... Zane Benefits, small businesses want to offer employee ... health insurance is unsustainable. Additionally, there are new ... portability, guaranteed-issue, and lower costs. , The ...
Breaking Medicine News(10 mins):Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:British Scientologist on a Mission to Save Youth from Drug Abuse 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3
... medications is associated with increased severity of erectile dysfunction, according ... British Journal of Urology International ., This study surveyed 37,712 ... taking various medications are likely to have more severe ED. ... multiethnic cohort of men ages 46 to 69 who are ...
... NJ . November 13, 2011. Kessler Foundation received a ... Geriatric Life Improvement. Anna Barrett, MD, director of Stroke ... to finding better ways to treat hidden disabilities that ... are pleased to receive this grant," said Rodger DeRose, ...
... By Serena Gordon HealthDay Reporter , MONDAY, Nov. ... warfarin need blood tests every four weeks to make sure ... suggests that some people could safely have those tests done ... isn,t an option for everyone on warfarin, just those who ...
... News) -- Drinking alcohol may be especially risky for young ... including having mothers, grandmothers or aunts with the disease, a ... Medicine in St. Louis examined data on more than 9,000 ... aged 9 to 15) through 2007. They focused on ...
... Indianapolis Wishard Health Services chief medical information officer, ... named one of America,s leading clinical informaticists by Modern ... Dr. Dexter is an associate professor of clinical medicine ... director of clinical applications at Wishard. "Dr. ...
... MONDAY, Nov. 14 (HealthDay News) -- Hearing loss affects ... far higher number than previously believed, researchers report. ... during National Health and Nutritional Examination Surveys (NHANES) from ... Organization,s definition of hearing loss (unable to hear sounds ...
Cached Medicine News:Health News:Erectile dysfunction increases with use of multiple medications 2Health News:Erectile dysfunction increases with use of multiple medications 3Health News:Kessler Foundation awarded stroke research grant by Wallerstein Foundation 2Health News:Warfarin May Need Less Monitoring for Some 2Health News:Warfarin May Need Less Monitoring for Some 3Health News:Drinking Risky for Women With Family History of Breast Cancer: Study 2Health News:Drinking Risky for Women With Family History of Breast Cancer: Study 3Health News:Indianapolis doc recognized as one of nation's top health info tech experts 2Health News:Indianapolis doc recognized as one of nation's top health info tech experts 3Health News:Hearing Loss Far More Common Than Expected 2
(Date:8/19/2014)... 19, 2014 According to Kalorama Information, electronic ... make Big Data in healthcare a reality, and this ... of the American Recovery and Reinvestment Act, the U.S. ... projects and penalties will start applying soon for use ... its complete study of the EMR industry, EMR ...
(Date:8/19/2014)... , Aug. 19, 2014  Regeneron Pharmaceuticals, Inc. (NASDAQ: ... conferences: , Sanofi and Regeneron will host an IR ... on Tuesday, September 2, 2014 , Baird 2014 ... September 3, 2014 , Citi,s 9 th ... Thursday, September 4, 2014 , Morgan Stanley Global ...
(Date:8/19/2014)... PARK, Calif. , Aug. 19, 2014   DelMar ... a protocol amendment to allow for expanded dosing in its ... and Drug Administration (FDA) and that a new cohort of ... clinical trial sites in the United States ... million have been raised through warrant exercise in two separate ...
Breaking Medicine Technology:Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7
... YORK, Nov. 17 Romeo and Juliette Laser ... hair removal center in New York City to own the ... leading developer and manufacturer of laser and light-based aesthetic treatment ... patented MultiPlex sequencing technology, is a highly versatile laser aesthetic ...
... , NEW YORK, Nov. 17 Engineer/pilot/attorney ... credit. They include technology that thwarts piracy in ... behind, devices to enhance airport security and even an ... interests that they have, indeed, found their match. ...
Cached Medicine Technology:Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System 2When Viruses (Including H1N1) and Bacteria are as Close as your Fingertips; VirWall's New Innovation Can Disarm Killer Keyboards 2
The ACMI TurboFlow 18 L and 10 L Insufflators provide rapid distention for all laparoscopic procedures. Eleven built-in safety features make insufflation reliable and dependable....
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
Medicine Products: